🔗 Share this article

Given that America continues making unprecedented changes to its immunization guidelines, an unexpected name has emerged somewhat surprisingly: Høeg, a Danish American sports medicine doctor and public health researcher who first made her name by casting doubt on coronavirus vaccinations during the global health crisis and has focused upon possible deaths after COVID-19 vaccination in her brief position at the US Food and Drug Administration (FDA).

Scheduled Shifts to Childhood Vaccine Schedule

Health officials planned to unveil major revisions to the pediatric immunization program recently, bringing the US with Denmark’s immunization schedule, it is understood – a significant shift that would place the US at odds with a large portion of the world with insufficient data for public health gain. The planned update has been delayed until the new year.

In place of the top vaccines chief, Tracy Beth Høeg is scheduled to address the audience at the meeting. She was just designated acting director of the FDA’s CDER, the fifth appointee to lead the center this year.

A New Direction at the FDA

The acting appointment might represent a strengthened alliance between the drug and vaccine branches as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it suggests a increased emphasis upon dismantling long-standing vaccines at the FDA.

The new acting director has often pushed for halting specific childhood immunization guidelines in the US so as to align more similar to the Danish model, a society with universal health coverage and a citizenry about the size of Wisconsin’s.

So far statements, she has continued to focus on vaccines – typically the domain of Prasad, director of the FDA’s CBER – instead of drug regulation.

Doubts Over Qualifications

Høeg has no obvious track record in pharmaceutical research, regulation or management, which has been typical for past leaders of the biologics center. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since March.

“She doesn’t seem to have the necessary background” for leading the pharmaceutical oversight division, stated Jonathan Howard. “She has not conducted a clinical trial. She has no expertise in managing a sizeable institution. She lacks background in drug approvals.”

Past heads of CBER would “understand legal statutes and the science of pharmaceutical innovation”, commented Janet Woodcock. “Clearly, she lacks the type of experience that former directors who headed the center have had.”

This division has an immense workload at the FDA, Woodcock pointed out.

“The public just pays attention on the new drug program, but the generic program clears numerous generic medications. There is also a biosimilars division, OTC medication office and so forth, and each of these have to be managed,” Dr. Woodcock explained. “The area you overlook, that is precisely what that I always told people is going to bite you.”

Furthermore, a significant management aspect to the position, which oversees over 5,000 employees. “It’s a enormous management job, if you do it right,” the former official added.

Official Statement and Disputed Initiatives

When asked about questions about Dr. Høeg's credentials and whether this assignment signifies greater collaboration among agency officials on vaccines, a representative responded that the “concerns stem from flawed premises”.

“Her experience matches the duties of her position,” the representative stated, noting the period Høeg spent guiding the FDA commissioner on “medication safety and approval science, including computerized risk analysis and shot safety tracking”.

As acting director, Høeg takes over the commissioner’s controversial expedited review system, a disputed expedited medication authorization process that allegedly concerned her predecessors. “How are these drugs being picked for this expedited pathway? Who takes the calls?” Howard asked. “There’s a lot of secrecy going on at the FDA right now.”

Broadly speaking, he stated, “the Food and Drug Administration looks to be trending towards less stringent rules of all drugs, with the exception of vaccines.”

Established Past Work on Immunizations

Regarding immunizations, Høeg has a clearer, if problematic, history, some experts observe. She published a research paper using unverified crowd-sourced reports to assess the frequency of myocarditis after COVID-19 vaccination. She advised the state of Florida top health official Joseph Ladapo, who was said to have altered data to imply COVID-19 vaccinations are more dangerous than they are.

Included in her “desired changes” for the new federal leadership included altering rules for new vaccines and discontinuing “unnecessary” immunizations, she said post-election on a online show. At the agency, Dr. Høeg has allegedly suggested preventing adolescent males from obtaining Covid vaccinations.

“She’s an all-around dogmatist who starts off with her beliefs and tailors the evidence to accommodate the science in a very deceptive, untruthful manner,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Høeg became part of fellow contrarians, {like|